Science is supposed to be gold standard, giving rigorous, impartial, and trustworthy advice on health treatments.

But increasingly, it’s looking more like a house of cards built on ghostwritten papers, corporate spin, short term outcome logging and a rush to market that leaves safety trailing in the dust.

You only need to browse job ads online to see the rise of “science writers” hired not to uncover truth, but to craft persuasive narratives. These ghostwriters often work behind the scenes, shaping studies and articles that carry the names of respected academics – while the real authors remain invisible. It’s a slick operation, and it’s dangerous to patient safety.

Take mesh implants. Once hailed as a miracle fix, they were aggressively marketed, pushed into operating theatres, and backed by “evidence” that was often flimsy at best. Only after thousands of women were harmed and campaigns set up to amplify women’s voices did the truth begin to surface. But by then, the damage was done.

This pattern isn’t new. It’s what Scott’s Parabola describes so well: a product is rushed to market, hyped to the heavens, and aggressively hustled until the cracks start to show. Then comes the slow, painful descent – when people realise it’s not safe, not effective, and not what they were promised.

Let’s break down the players in this troubling game.

1. Pharma – profit over people

Pharmaceutical and medical device companies have one clear goal: profit. They’re beholden to shareholders, not patients. Evidence is cherry-picked, risks are downplayed, and benefits overstated. They fund conferences, training, and research – not out of generosity, but to control the narrative and keep the sales flowing.

2. Key Opinion Leaders – the career dancers

These are the academics and clinicians who appear on panels, publish papers, and lend credibility to products. But many are compromised. Their conflicts of interest are buried deep, and their loyalty often lies with career advancement, conference speaker gigs and ego, not public safety. Spotting them takes a sharp nose. They’re polished and persuasive. Funding may be quietly channelled into initiatives like surgeon societies such as The Pelvic Floor Society founded by disgraced rectopexy mesh surgeon and key opinion leader Tony Dixon who was struck off by the GMC in 2025.

3. Scientific Journals – authority for sale

Journals were once the gatekeepers of quality science. Now, many are just businesses chasing impact factors and citations. The prestige of publication has become a substitute for actual scientific merit. And when journals rely on industry funding, their objectivity is compromised.

4. Governments and Lobbyists – the enablers

Political bodies and lobby groups may turn a blind eye or don’t understand the impact of poor science – or worse, actively support harmful products. Regulations are watered down, safety checks are skipped, and public health takes a back seat to economic interests.

5. Short-term outcome logging – skewed results

Much of the science supporting mesh use only tracked women for six weeks to three months. However, mesh has a ticking timebomb quality, with some complications taking months or even years to emerge. This means a significant portion of the scientific literature is not worth the paper it’s printed on, as it fails to capture long-term harm.

6. Ask the wrong questions – get the wrong results

Much of the scientific research on mesh focuses on treating the original condition – like prolapse, incontinence, or hernia – rather than the complications that can follow surgery. In our support group, thousands report that while their initial issue was resolved, they now suffer from worse problems such as chronic pain, autoimmune disorders, and allergies. Patients will be listed in medical literature as success stories, yet now rely on walking aids, have had organs removed due to mesh damage, or among women had mesh slice their vaginal walls or among men suffered injuries like severed spermatic cords.

6a. The Pad Test – outcome measure fails

At the six-week follow-up after bladder mesh sling surgery, many women report being asked just one question by their surgeon: “How many TENA pads are you using now?” If the answer is “none,” the surgery is marked as a success. But this narrow metric ignores the full picture. Many of our members say they no longer leak  yet they leave the appointment in excruciating pain, struggling to walk, sit, or function normally. Their lives have been upended, and they are left desperately seeking referrals for mesh removal in a bid to reclaim their quality of life.

---

So where does that leave us?

It leaves us needing to ask harder questions.

We must demand transparency with Sunshine legislation which would force industry to publicly disclose payments to the health sector on a central government held database.

Also, mandatory reporting of adverse events to the MHRA Yellow Card system by healthcare professionals is urgently needed. Currently, the system relies on voluntary submissions, leading to serious underreporting. A stark example occurred in 2012, when 1,000 women returned to hospital with complications from bladder mesh sling surgery. Shockingly, only four of these cases were recorded in the Yellow Card system. This lack of data allowed government and regulatory bodies to claim that mesh complications were rare – misrepresenting the true scale of harm.

We need longer term outcome logging and quality of life questionnaires that capture new onset of complications – including free text boxes where patients can report  unexpected complications which would help spot trends of harm.

Conclusion

It is vital we challenge the glossy brochures and the “expert” endorsements. And to remember that behind every rushed product and every ghostwritten paper, there are real people – like patients harmed by mesh – paying the price.

Science should serve the public. Not shareholders. Not careers. Not corporate agendas. Not egos.

It’s time to reclaim it.